Gilead Sciences has struck a licensing agreement with five generic drugmakers to make antiviral drug remdesivir for 127 countries, not including the United States, the company announced Tuesday. Drugmakers Mylan, Cipla, Ferozsons Laboratories, Hetero Labs and Jubilant Lifesciences will manufacture remdesivir for distribution in "low-income and lower-middle-income countries, as well as several upper-middle- and high-income countries" that face health-care obstacles amid the coronavirus pandemic, the company said. SEE ALSO REMDESIVIR IS THE NEW DRUG BEING USED TO TREAT CORONAVIRUS The deal is "royalty-free" until the World Health Organization says the Covid-19 outbreak is no longer a global health crisis or "until a pharmaceutical product other than remdesivir or a vaccine is approved to treat or prevent Covid-19, whichever is earlier," the company said. The Food and Drug Administration on May 1 granted emergency use authorization for Gilead's remdesi...
Visit for daily Kenyan news, breaking news, celebrity, top headline updates, international news, important health issues, and worldwide hot articles.